The networking event takes place with physical presence on site in Basel, Switzerland, 20-22 March and is expected to bring together over 2,800 senior executives from around the world to participate in more than 15,000 individual meetings. The event is followed by a digital on 28-30 March in which Klaus Christensen also will attend.

"This is the first time BIO-Europe Spring is taking place physically since the pandemic, which creates unique opportunities to conduct one-to-one meetings on site with potential partners. I will present Foxy-5, our observations in the ongoing phase 2 study but also point out the great needs that exist, how Foxy-5 could be combined with other standard treatments and thus the commercial potential" says Klaus Christensen.

For further information:

Klaus Christensen, CCO WntResearch AB
e-post: kc@wntresearch.com

About Wntresearch AB

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com. Follow WntResearch on Linked in